Current research of prostate cancer (PCa) offers a promising way of identifying patients with adverse prognosis who do benefit from radical treatment that can affect quality of life as resections are associated with numerous side-effects. The aim of our study was to evaluate the relationship of TMPRSS2-ERG fusion gene status, tumor tissue prostate-specific antigen (PSA), prostate cancer antigen 3 (PCA3), miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy.
The study group consisted of 108 patients who underwent radical prostatectomy. PSA was measured in peripheral blood collected preoperativelly. The expression of TMPRSS2-ERG transcript and the expression of miR-23b, miR-26a and miR-221 in formalin-fixed, paraffin-embedded (FFPE) tumor tissues was analyzed by reverse transcription (RT) real-time polymerase chain reaction (PCR).
Significantly shorter time to recurrence was observed in patients with high expression of TMPRSS2-ERG (p=0.0020). High levels of preoperative PSA (>10.0 ng/ml) proved to be marker of shorter time to recurrence (p=0.0153). The most promising marker of the risk of recurrence after radical prostatectomy was a combination of high level of preoperative serum PSA and high expression of TMPRSS2-ERG fusion transcript in tumor tissue (p=0.0001).
A combination of high preoperative serum PSA and high expression of TMPRSS2-ERG could be promising in distinguishing those tumors that are aggressive and life-threatening.
Anticancer research. 2016 Sep [Epub]
Vlastimil Kulda, Ondrej Topolcan, Radek Kucera, Michaela Kripnerova, Kristyna Srbecka, Milan Hora, Ondrej Hes, Jiri Klecka, Vaclav Babuska, Milena Rousarova, Veronika Benson, Martin Pesta
Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic., Department of Nuclear Medicine - Immunoanalytic Laboratory, University Hospital in Pilsen, Pilsen, Czech Republic., Department of Biology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic., Department of Urology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic., Department of Pathology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic., Urocentrum Plzen, Pilsen, Czech Republic., Institute of Microbiology, v.v.i., Academy of Sciences of the Czech Republic, Prague, Czech Republic., Department of Biology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic .